HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
-
BUSINESS Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
-
REGULATORY Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat
July 14, 2017
-
ACADEMIA JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer
July 14, 2017
-
REGULATORY Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting
July 13, 2017
-
REGULATORY MHLW to Announce Data Required for Conditional Early Approval
July 12, 2017
-
ACADEMIA New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment
July 11, 2017
-
BUSINESS Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
-
BUSINESS Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
-
BUSINESS RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
-
BUSINESS AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race
July 7, 2017
-
BUSINESS Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations
July 6, 2017
-
REGULATORY Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments
July 6, 2017
-
BUSINESS Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen
July 5, 2017
-
BUSINESS Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs
July 4, 2017
-
BUSINESS Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation
July 3, 2017
-
REGULATORY MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
-
REGULATORY “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo
June 29, 2017
-
REGULATORY Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method
June 29, 2017
-
BUSINESS Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec
June 28, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…